News

Filter

Current filters:

NovoLogNovo Nordisk

Mylan extends deal with Biocon to biosimilar insulins, as Actavis pulls out of JV

14-02-2013

US generic drugmaker Mylan (Nasdaq: MYL) said yesterday that it has entered into a definitive agreement…

ActavisBioconBiotechnologyDiabetesEli LillyGenericsHumalogLantusLicensingMarkets & MarketingMylan LaboratoriesNovo NordiskNovoLogSanofi

Novo Nordisk boosts US sales force

11-12-2006

Denmark's Novo Nordisk plans to expand its diabetes care field force in the USA, from around 1,200 to…

Humulin 70-30Humulin NHumulin RInsulinInsulin Aspart [rDNA origin] InjInsulin DetemirLevemirNovo NordiskNovoLog

Novo Nordisk's first-half sales rise 15%

22-08-2005

Copenhagen, Denmark-headquartered drugmaker Novo Nordisk says that its revenue in the first half of 2005…

Antihemophilic FactorCoagulation Factor VIIaHumulin 70-30Humulin NHumulin RInsulinInsulin Aspart [rDNA origin] InjNovo NordiskNovoLogNovoSevenRecombinant

NovoLog FlexPen launched in USA

10-03-2003

Novo Nordisk has launched its rapid-acting insulin product NovoLog(insulin aspart) in the USA in a new…

Humulin 70-30Humulin NHumulin RInsulinInsulin Aspart [rDNA origin] InjNovo NordiskNovoLog

Novo insulin analog launched in USA

19-09-2001

Denmark's Novo Nordisk has launched a new rapid-acting insulin analog,NovoLog (insulin aspart), in the…

HumalogHumalog Mix 50-50Humulin 70-30Humulin NHumulin RInsulinInsulin Aspart [rDNA origin] InjInsulin LisproLillyNovo NordiskNovoLog

Novo Nordisk gains FDA OK for NovoLog

08-06-2000

The US Food and Drug Administration has approved Novo Nordisk'sNovoLog (insulin aspart) for use in treating...

Humulin 70-30Humulin NHumulin RInsulinInsulin Aspart [rDNA origin] InjNovo NordiskNovoLog

Back to top